Second International Congress Drug Therapy in HIV Infection 18-22 November 1994 Glasgow, UK

THE TREATMENT OF KAPOSI'S SARCOMA WITH CYTOTOXIC AGENTS

Karen A. Gelmon
British Columbia Cancer Agency, Vancouver, Canada

Int Cong Drug Therapy HIV 1994 Nov 18-22;2:Abstract No. 13.2
AIDS 1994, Vol. 8 (Suppl. 4);S11

The treatment of Kaposi's sarcoma with cytotoxic agents has many controversies. Although a number of agents including the vinca alkaloids such as vincristine and vinblastine, etoposide, adriamycin, bleomycin and liposomal doxorubicin, have been shown to give significant response rates, both partial responses (PR) and complete responses (CR), these responses are often mixed and transient. Controversies in the treatment of Kaposi's sarcoma with chemotherapy also extend to when to introduce drugs and whether chemotherapy should be given in isolation or with other modifiers such as interferon. Combination chemotherapy, particularly adriamycin, bleomycin and vincristine (ABV) have been given with adequate response rates but are often associated with significant toxicity. The use of cytokines such as G or GMCSF to allow adequate dose increments has been associated with hematological tolerance but has not yet been reported to give better response rates in published trials. As well, many patients presenting with end stage HIV illness and KS are on a multitude of other drugs which limit adequate delivery of cytotoxics.

In the light of the round-table discussion of other types of treatment,the chemotherapy of KS will be discussed both in terms of its indications and pitfalls. New cytotoxic agents such as paclitaxel are also under investigation and will be discussed.

Presenting author: Karen A. Gelmon

1994-11-18
13.2

Originally published in AIDS Volume 8, Supplement 4 and hosted with permission of the publisher Lippincott Williams & Wilkins, 250 Waterloo Road, London, SE1 8RD, UK. Tel: +44 (0)20 7981 0700 Fax: +44 (0) 7981 0701

Copyright © 1994 - Lippincott Williams & Wilkins. All rights reserved. All abstracts from the 2nd International Congress Drug Therapy in HIV Infection, appearing on the AEGiS web site, are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Lippincott Williams & Wilkins. You may not alter or remove any trademark, copyright or other notice. However, provided that you maintain all copyright and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only.

http://www.aidsonline.com http://www.ovid.com